Key Takeaways RMD posted Q2 EPS of $2.81, up 15.6% year over year, beating consensus alongside 11% revenue growth.Resmed expanded adjusted gross margin to 62.6% and operating margin to 36.6%, as profit outpaced costs.RMD saw double-digit growth in Sleep and Breathing Health, while Residential Care Software rose 6.6%.Resmed Inc.’s (RMD) adjusted earnings per share (EPS) in the second quarter of fiscal 2026 were $2.81, up 15.6% year over year. The metric beat the Zacks Consensus Estimate by 4.59%.The adjustme ...

2026 年 1 月底， ResMed 瑞思迈 披露截至 2025 年 12 月 31 日的 2026 财年第二季度业绩： 尽管财务表现超预期，股价在财报发布后短期小幅波动，反映市场对中长期竞争变量的持续关注。 # 增长来源拆解：并非单一产品驱动 瑞思迈在公告中强调，本季度增长并非来自单一爆款，而是 多条业务线同步推进 ： 1. 睡眠设备：新增患者基础的核心入口 2. 面罩与配件：高毛利、强复购的稳定器 季度营收 ：14.2 亿美元，同比增长 11% GAAP 净利润 ：3.93 亿美元，同比增长 13.9% GAAP EPS ：2.68 美元 调整后 EPS ：2.81 美元，显著高于市场预期 CPAP 与双水平呼吸机持续放量 AirSense 系列仍是主要收入来源 # 监管与产品进展：以体验优化为导向 在本季度内，瑞思迈获得 Smart Comfort 个性化治疗方案 的 FDA 准入。 公司并未将其描述为"颠覆性创新"，而是作为提升患者舒适度与长期依从性的补充方案。 这一表述逻辑，与瑞思迈长期以来" 改善使用体验 → 提升依从性 → 稳定复购 "的商业模型保持一致。 面罩及耗材随设备保有量增长 构成公司 ...

The Zacks Medical - Products industry is grappling with a challenging operating environment due to the tariffs imposed by the United States on multiple trading partners, including China, Europe and India. The increasing tariff rates are hurting the margins of several medical device makers, including GE HealthCare, Baxter and Abbott.The medical device makers have faced a persistent rise in commodity and manufacturing costs post COVID-19, particularly in consumer-facing areas like Nutrition. Price hikes imple ...

Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for apnea, calling the GLP1 bo... ...

Company Overview - ResMed is a $37 billion company that positions itself as a "36-year-old startup" in the sleep and breathing health sector [1] - The company is the leading provider in over 140 countries, holding a market share of 50–60% in sleep apnea devices, including CPAP machines and masks [1] Investment Perspective - The company is focused on identifying undervalued stocks with a strong emphasis on balancing risk and reward [1] - There is a belief that the best investment ideas are often the simplest, and a contrarian approach may yield better results [1]

Company Overview - ResMed is a $37 billion company that positions itself as a "36-year-old startup" in the sleep and breathing health sector [1] - The company is the leading provider in over 140 countries, holding a market share of 50–60% in sleep apnea devices, including CPAP machines and masks [1] Investment Perspective - The company is focused on identifying undervalued stocks with a favorable risk-reward profile, emphasizing limited risks and potential for decent to high upside [1] - The belief is that the best investment ideas are often the simplest, with a contrarian approach being favored [1]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Insights - ResMed Inc reported second-quarter fiscal 2026 adjusted earnings of $2.81, exceeding the consensus estimate of $2.72 [1] - Quarterly sales rose 11% year over year to $1.42 billion, surpassing the consensus estimate of $1.396 billion [1] - Sales increased 9% on a constant currency basis, driven by higher demand for sleep devices, masks, and accessories [1] - Residential Care Software revenue grew by 5% on a constant currency basis [1] Product Development - In December 2025, the FDA cleared ResMed's Personalized Therapy Comfort Settings (PTCS) for marketing as Smart Comfort, the first AI-enabled medical device for obstructive sleep apnea patients [2] - Smart Comfort is set to launch in early 2026 in a limited U.S. beta version for new users of the myAir app, with a broader rollout planned later in 2026 [3] Financial Performance - Gross margin increased by 320 basis points to 61.8%, driven by manufacturing and logistics efficiencies [3] - Adjusted gross margin rose by 310 basis points to 62.3% [3] - Adjusted operating income increased 19% to $517.2 million [4] Future Outlook - ResMed anticipates revenue growth at a high single-digit rate over the next five years, with earnings expected to outpace revenue growth [5] Analyst Reactions - Analysts from William Blair support the bull thesis for ResMed, projecting strong double-digit EPS growth of +15% this year [6] - Stifel raised the price forecast from $260 to $265, while Wells Fargo increased it from $265 to $270, and Piper Sandler from $270 to $275 [7] - ResMed shares were down 2.33% at $251.62 as of the last check on Friday [7]

In Canada and Latin America, constant-currency device sales increased 8% and masks and other sales increased 16% , which management attributed to growth in both resupply and new patient setups, as well as incremental revenue from the VirtuOx acquisition completed in the fourth quarter of fiscal 2025.Excluding revenue from the Residential Care Software (RCS) business, Sandercock said sales in the U.S., Canada and Latin America rose 11% (and 6% on a constant currency basis). Globally, on a constant currency b ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________________________________________________________________ FORM 10-Q ______________________________________________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 F ...